Sado Keina, Keenan Katherine, Manataki Areti, Kesby Mike, Mushi Martha F, Mshana Stephen E, Mwanga Joseph, Neema Stella, Asiimwe Benon, Bazira Joel, Kiiru John, Green Dominique L, Ke Xuejia, Maldonado-Barragán Antonio, Abed Al Ahad Mary, Fredricks Kathryn, Gillespie Stephen H, Sabiiti Wilber, Mmbaga Blandina T, Kibiki Gibson, Aanensen David, Smith V Anne, Sandeman Alison, Sloan Derek J, Holden Matthew Tg
University of St Andrews, St Andrews, UK.
Catholic University Of Health And Allied Sciences, Mwanza, Tanzania.
medRxiv. 2023 Mar 20:2023.03.04.23286801. doi: 10.1101/2023.03.04.23286801.
Antibacterial resistance (ABR) is a major public health threat. An important accelerating factor is treatment-seeking behaviours, including inappropriate antibiotic (AB) use. In many low- and middle-income countries (LMICs) this includes taking ABs with and without prescription sourced from various providers, including health facilities and community drug sellers. However, investigations of complex treatment-seeking, AB use and drug resistance in LMICs are scarce. The Holistic Approach to Unravel Antibacterial Resistance in East Africa (HATUA) Consortium collected questionnaire and microbiological data from 6,827 adult outpatients with urinary tract infection (UTI)-like symptoms presenting at healthcare facilities in Kenya, Tanzania and Uganda. Among 6,388 patients we analysed patterns of self-reported treatment seeking behaviours ('patient pathways') using process mining and single-channel sequence analysis. Of those with microbiologically confirmed UTI (n=1,946), we used logistic regression to assessed the relationship between treatment seeking behaviour, AB use, and likelihood of having a multi-drug resistant (MDR) UTI. The most common treatment pathways for UTI-like symptoms included attending health facilities, rather than other providers (e.g. drug sellers). Patients from the sites sampled in Tanzania and Uganda, where prevalence of MDR UTI was over 50%, were more likely to report treatment failures, and have repeated visits to clinics/other providers, than those from Kenyan sites, where MDR UTI rates were lower (33%). There was no strong or consistent relationship between individual AB use and risk of MDR UTI, after accounting for country context. The results highlight challenges East African patients face in accessing effective UTI treatment. These challenges increase where rates of MDR UTI are higher, suggesting a reinforcing circle of failed treatment attempts and sustained selection for drug resistance. Whilst individual behaviours may contribute to the risk of MDR UTI, our data show that factors related to context are stronger drivers of ABR.
抗菌药物耐药性(ABR)是对公众健康的重大威胁。一个重要的加速因素是寻求治疗的行为,包括不适当使用抗生素(AB)。在许多低收入和中等收入国家(LMICs),这包括从包括医疗机构和社区药品销售商在内的各种提供者处获取有处方和无处方的抗生素。然而,对低收入和中等收入国家复杂的寻求治疗行为、抗生素使用和耐药性的调查很少。东非揭示抗菌药物耐药性整体方法(HATUA)联盟收集了来自肯尼亚、坦桑尼亚和乌干达医疗机构中6827名有尿路感染(UTI)样症状的成年门诊患者的问卷和微生物学数据。在6388名患者中,我们使用过程挖掘和单通道序列分析来分析自我报告的寻求治疗行为模式(“患者路径”)。在那些微生物学确诊为UTI的患者(n = 1946)中,我们使用逻辑回归来评估寻求治疗行为、抗生素使用与多重耐药(MDR)UTI可能性之间的关系。UTI样症状最常见的治疗途径包括前往医疗机构,而不是其他提供者(如药品销售商)。在坦桑尼亚和乌干达抽样地点,MDR UTI患病率超过50%,与来自肯尼亚地点(MDR UTI率较低,为33%)的患者相比,这些地点的患者更有可能报告治疗失败,并且多次前往诊所/其他提供者处就诊。在考虑国家背景后,个体抗生素使用与MDR UTI风险之间没有强烈或一致的关系。结果突出了东非患者在获得有效的UTI治疗方面面临的挑战。在MDR UTI发生率较高的地方,这些挑战会增加,这表明治疗尝试失败和持续选择耐药性形成了一个强化循环。虽然个体行为可能会增加MDR UTI的风险,但我们的数据表明,与背景相关的因素是ABR的更强驱动因素。